Volver al Panel








Vertex Pharmaceuticals Incorpor (VRTX)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
VRTX Intraday
No data available
SímboloVRTX
Fecha de SalidaJul 24, 1991
CEODr. Jeffrey Marc Leiden M.D., Ph.D.
Empleados a Tiempo Completo6.4k
SectorHealthcare
IndustriaBiotechnology
PaísUnited States
BolsaNasdaqGS
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | -1.11% | -5.76 US$ |
| 5 Días | -4.40% | -23.70 US$ |
| 1 Mes | -1.84% | -9.63 US$ |
| 6 Meses | +18.50% | +80.38 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de VRTX...
Estadísticas Clave
Cap. de Mercado
130.58B
Relación P/E
33.14
Rend. de Div.
0.00%
Máx. 52 Semanas
$568.67
Mín. 52 Semanas
$412.27
Consenso de Analistas
CONSENSOCompra
ALCISTA2681.3%
NEUTRAL515.6%
BAJISTA13.1%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$350.00
$350.00
Objetivo Máx.
$725.00
$725.00
Actual$514.89
Objetivo Prom.$595.36
Recomendaciones de Analistas
Precio Objetivo:$595.36($350.00 - $725.00)
¿Buscas más valores? Explóralos en el screener
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre VRTX
Únase a la comunidad para compartir su análisis
Últimas Noticias para VRTX

Is It Too Early To Buy Insmed Stock?
Trefis•20 nov 2026, 14:29

Has Vertex Stock Become A Different Bet?
Trefis•20 nov 2026, 12:28

2 Growth Stocks to Buy in November Without Any Hesitation
Motley Fool•19 nov 2026, 18:03

Genomics, Vertex extend drug discovery alliance in $220m deal
Pharmaceutical Technology•19 nov 2026, 10:53

Should You Pick Vertex Stock Over Its Biotech Rivals?
Trefis•18 nov 2026, 17:13

The Women’s Edge and The Boston Globe Again Name CCC to Top 100 Women-Led Businesses in Massachusetts List
GlobeNewswire•18 nov 2026, 13:30
iShares Biotechnology ETF (IBB) Buys $16.2 Million More Gilead on Nov. 16
GuruFocus.com•18 nov 2026, 11:05
Capital Group Growth (CGGR) Buys $56.4 Million More Cloudflare on Nov. 16
GuruFocus.com•18 nov 2026, 11:05

Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals
PR Newswire•18 nov 2026, 09:43

Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals
PR Newswire•18 nov 2026, 09:29